Company registration number 13030401 (England and Wales)
FAIRLIGHT PHARMA LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026
PAGES FOR FILING WITH REGISTRAR
FAIRLIGHT PHARMA LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 8
FAIRLIGHT PHARMA LIMITED
BALANCE SHEET
AS AT
30 APRIL 2026
30 April 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
3
1,439,014
1,478,173
Tangible assets
4
217,305
98,671
1,656,319
1,576,844
Current assets
Stocks
250,538
147,328
Debtors
5
601,490
436,012
Cash at bank and in hand
155,705
364,490
1,007,733
947,830
Creditors: amounts falling due within one year
6
(511,093)
(510,450)
Net current assets
496,640
437,380
Total assets less current liabilities
2,152,959
2,014,224
Creditors: amounts falling due after more than one year
7
(1,404,553)
(1,430,047)
Provisions for liabilities
(24,077)
(24,077)
Net assets
724,329
560,100
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
724,229
560,000
Total equity
724,329
560,100
FAIRLIGHT PHARMA LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2026
30 April 2026
- 2 -
For the financial year ended 30 April 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 20 July 2026 and are signed on its behalf by:
Mr AH Jamel
Director
Company registration number 13030401 (England and Wales)
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026
- 3 -
1
Accounting policies
Company information
Fairlight Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, HA5 5QA.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.
The company has taken advantage of the exemption under section 399 of the Companies Act 2006 not to prepare consolidated accounts, on the basis that the group of which this is the parent qualifies as a small group. The financial statements present information about the company as an individual entity and not about its group.
1.2
Going concern
Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Revenue
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
1.4
Intangible fixed assets - goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2021 and September 2024, is being amortised evenly over its estimated useful life of forty years.
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Leasehold land and buildings
Over the lease term
Fixtures and fittings
10% on reducing balance
Motor vehicles
10% on reducing balance
1.6
Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2026
1
Accounting policies
(Continued)
- 4 -
1.7
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
Taxation for the period comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.8
Retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
1.9
Leases
As lessee
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2026
1
Accounting policies
(Continued)
- 5 -
1.10
The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2026
2025
Number
Number
Total
18
15
3
Intangible fixed assets
Goodwill
£
Cost
At 1 May 2025 and 30 April 2026
1,566,354
Amortisation and impairment
At 1 May 2025
88,181
Amortisation charged for the year
39,159
At 30 April 2026
127,340
Carrying amount
At 30 April 2026
1,439,014
At 30 April 2025
1,478,173
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2026
- 6 -
4
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Motor vehicles
Total
£
£
£
£
Cost
At 1 May 2025
2,486
103,031
49,362
154,879
Additions
143,023
22,799
165,822
Disposals
(49,363)
(49,363)
At 30 April 2026
2,486
246,054
22,798
271,338
Depreciation and impairment
At 1 May 2025
124
29,888
26,196
56,208
Depreciation charged in the year
124
21,616
2,280
24,020
Eliminated in respect of disposals
(26,195)
(26,195)
At 30 April 2026
248
51,504
2,281
54,033
Carrying amount
At 30 April 2026
2,238
194,550
20,517
217,305
At 30 April 2025
2,362
73,143
23,166
98,671
Included within the net book value of £217,305 is £20,517 (2025: £23,166) relating to assets held under hire purchase agreements. The depreciation charged to the financial statements in the year in respect of such assets amounted to £2,280 (2025: £5,792).
5
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
183,881
185,908
Other debtors
360,062
232,080
Prepayments and accrued income
57,547
18,024
601,490
436,012
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2026
- 7 -
6
Creditors: amounts falling due within one year
2026
2025
£
£
Bank loans and overdrafts
63,940
61,156
Trade creditors
230,312
306,280
Taxation and social security
63,869
38,955
Other creditors
152,972
104,059
511,093
510,450
7
Creditors: amounts falling due after more than one year
2026
2025
Notes
£
£
Bank loans and overdrafts
1,343,873
1,368,547
Obligations under finance leases
60,680
61,500
1,404,553
1,430,047
Creditors which fall due after five years are payable as follows:
Payable by instalments
1,089,713
1,123,921
The bank loans and overdrafts falling due less than 1 year and after more than 1 year are secured by a fixed and floating charge over the assets of the company.
The following assets held as security are charged to Barclays:
1) A debenture granted by Fairlight Pharma Limited in favour of Barclays.
2) A legal mortgage over 22 London Road, Twickenham, Middlesex, granted by Fairlight Pharma Limited and held for the benefit of Barclays.
3) A legal mortgage over 186 Rowan Road, London, SW16 5HX, held for the benefit of Barclays.
4) A corporate guarantee provided by A. C. Curd (Isleworth) Limited in favour of Barclays.
5) A corporate guarantee provided by Fairlight London Limited in favour of Barclays.
6) A corporate guarantee provided by Med Zone Limited in favour of Barclays.
7) A personal guarantee provided by Mr A Jamel and Mrs M Kalantari in favour of Barclays.
8
Related party transactions
2026
2025
Amounts due to related parties
£
£
Entities with common controlling shareholders and directors
63,245
3,577
The above disclosed amount is included within other creditors due within one year. The loan is unsecured, interest-free, and repayable on demand.
2026
2025
FAIRLIGHT PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2026
8
Related party transactions
(Continued)
- 8 -
Amounts due from related parties
£
£
Entities with common controlling shareholders and directors
261,675
144,168
The above disclosed amount is included within other debtors due within one year. The loan is unsecured, interest-free, and repayable on demand.
9
Directors' transactions
Dividends totalling £96,100 (2025 - £109,581) were paid in the year in respect of shares held by the company's directors.
During the year, Mr AH Jamel borrowed £101,374 from the company. This was the maximum amount of the loan outstanding at any point of the year. Interest on the loan was charged at the official rate.
Loans
% Rate
Opening balance
Amounts advanced
Interest charged
Amounts repaid
Closing balance
£
£
£
£
£
Mr AH Jamel -
3.75
-
101,374
833
(34,291)
67,916
-
101,374
833
(34,291)
67,916